Meta-Analysis
Copyright ©The Author(s) 2021.
World J Hepatol. Aug 27, 2021; 13(8): 949-968
Published online Aug 27, 2021. doi: 10.4254/wjh.v13.i8.949
Table 3 Area under the receiver operating characteristic curves of non-invasive tests for overall mortality, liver-related mortality, and composite outcomes
Ref.
NIT1
Outcome
AUROC (95%CI)
Chalouni et al[18], 2019APRI OM 0.58 (N/A)
LRM0.80 (N/A)
LRE 0.75 (N/A)
FIB-4 OM0.66 (N/A)
LRM0.88 (N/A)
LRE 0.78 (N/A)
TE OM0.69 (N/A)
LRM0.88 (N/A)
LRE 0.88 (N/A)
Hansen et al[20], 2019TE OM0.70 (0.62–0.78)
LRM0.93 (0.89–0.98)
HD (HCC included)0.89 (0.82–0.97)
Munteanu et al[22], 2018Fibrotest OM0.74 (0.71-0.77)
LRM0.88 (0.85-0.90)
Thandassery et al[43], 2017APRI (Pre-Rx)HD0.54 (0.06–0.78)
FIB-4 (Pre-Rx)HD0.85 (0.74–0.96)
Pérez-Latorre et al[24], 2016TE OMEstimation cohort 0.87 (0.84-0.90)
Validation cohort 0.88 (0.84-0.91)
Lee et al[46], 2016TE (Post-Rx)A composite outcome of HD, HCC, and/or LRM0.92 (0.84-1.00)
Berenguer et al[12], 2015FIB-4 (Pre-Rx)LRE (HD or HCC)0.75 (0.72-0.78)
Yu et al[11], 2006APRI (Pre-Rx)OM0.53 (0.35-0.72)
APRI (Post-Rx)OM0.87 (0.81-0.93)